BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Funds and ETFs Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Equities
603392
CNE100004090
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.04 CNY | -0.75% |
|
-7.38% | -12.10% |
| Apr. 12 | Wantai Biological's Phase 3 Trials for Nine-Valent HPV Vaccine Yields Performed 'As Expected' | MT |
| Mar. 29 | Wantai BioPharm's 2023 Profit Drops 74% on Revenue Drop; Shares Slump 3% | MT |
ETFs positioned on Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.43% | 2 M€ | -18.98% | - | |
| 0.93% | 12 M€ | -16.71% | - | |
| 0.10% | 11 M€ | +0.34% | ||
| 0.08% | 35 M€ | -5.85% | - | |
| 0.07% | 2 M€ | -.--% | ||
| 0.04% | 7 M€ | -.--% | - | |
| 0.01% | 441 M€ | +2.75% | - | |
| 0.01% | 2,808 M€ | +4.06% | - | |
| 0.01% | 149 M€ | -0.66% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.78% | - | |
| 0.00% | 389 M€ | +5.99% | - | |
| 0.00% | 34 M€ | +5.05% | - | |
| 0.00% | 39 M€ | +2.90% | - | |
| 0.00% | 302 M€ | +3.83% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 17 M€ | +0.96% | - | |
| 0.00% | 108 M€ | +1.85% | - | |
| 0.00% | 34 M€ | +2.09% | - | |
| 0.00% | 7 M€ | +1.16% | - | |
| 0.00% | 52 M€ | -0.45% | - | |
| 0.00% | 8 M€ | -0.80% | - | |
| 0.00% | 15 M€ | +7.47% |
Beijing Wantai Biopharmaceutical Co., Ltd. is a company mainly engaged in the research and development, production and sales of in-vitro diagnostics. The Company produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The Company is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
66.04
CNY
Average target price
75.15
CNY
Spread / Average Target
+13.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.10% | 11.65B | |
| -2.68% | 85.68B | |
| +4.08% | 41.4B | |
| -25.06% | 28.22B | |
| +54.31% | 24.64B | |
| -4.64% | 16.98B | |
| -42.09% | 13.29B | |
| -17.38% | 11.66B | |
| +0.75% | 8.18B | |
| +5.19% | 7.78B |
- Stock Market
- Equities
- 603392 Stock
- Funds and ETFs Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
